hematologic diseases

Summary

Summary: Disorders of the blood and blood forming tissues.

Top Publications

  1. pmc In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology
    Michelle Tsai
    Department of Bioengineering, University of California, Berkeley, California, USA
    J Clin Invest 122:408-18. 2012
  2. pmc Deletion of KDM6A, a histone demethylase interacting with MLL2, in three patients with Kabuki syndrome
    Damien Lederer
    Centre de Genetique Humaine, Institut de Pathologie et Genetique, Charleroi, Belgium
    Am J Hum Genet 90:119-24. 2012
  3. pmc Mutation spectrum of MLL2 in a cohort of Kabuki syndrome patients
    Lucia Micale
    Medical Genetics Unit, IRCCS Casa Sollievo della Sofferenza Hospital, 71013 San Giovanni Rotondo, Italy
    Orphanet J Rare Dis 6:38. 2011
  4. ncbi Analyzing cell mechanics in hematologic diseases with microfluidic biophysical flow cytometry
    Michael J Rosenbluth
    Department of Bioengineering, 608B Stanley Hall, Berkeley, CA 94720 3220, USA
    Lab Chip 8:1062-70. 2008
  5. ncbi Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
    Katherine K Matthay
    Department of Pediatrics, University of California at San Francisco, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 25:1054-60. 2007
  6. pmc Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory
    Wanming Zhao
    Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    J Hematol Oncol 4:4. 2011
  7. ncbi A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer
    John M Kirwan
    Liverpool Women s Hospital, Crown Street, Liverpool L78 7SS, UK
    Radiother Oncol 68:217-26. 2003
  8. ncbi Mutations in SBDS are associated with Shwachman-Diamond syndrome
    Graeme R B Boocock
    Program in Genetics and Genomic Biology, Room 11 109A, Elm Wing Annex, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada
    Nat Genet 33:97-101. 2003
  9. pmc CD4+CD25highFoxP3+ regulatory T-cells in hematologic diseases
    Hee Won Moon
    Department of Laboratory Medicine, Konkuk University School of Medicine, Hospital, 4 12 Hwayang dong, Gwangjin gu, Seoul, Korea
    Korean J Lab Med 31:231-7. 2011
  10. ncbi Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
    John E Wagner
    Blood and Marrow Transplant Program of the Department of Pediatrics, University of Minnesota Cancer Center and School of Medicine, Minneapolis 55455, USA
    Blood 100:1611-8. 2002

Detail Information

Publications230 found, 100 shown here

  1. pmc In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology
    Michelle Tsai
    Department of Bioengineering, University of California, Berkeley, California, USA
    J Clin Invest 122:408-18. 2012
    In hematologic diseases, such as sickle cell disease (SCD) and hemolytic uremic syndrome (HUS), pathological biophysical interactions among blood cells, endothelial cells, and soluble factors lead to microvascular occlusion and thrombosis...
  2. pmc Deletion of KDM6A, a histone demethylase interacting with MLL2, in three patients with Kabuki syndrome
    Damien Lederer
    Centre de Genetique Humaine, Institut de Pathologie et Genetique, Charleroi, Belgium
    Am J Hum Genet 90:119-24. 2012
    ..This study identifies KDM6A mutations as another cause of KS and highlights the growing role of histone methylases and histone demethylases in multiple-congenital-anomaly and intellectual-disability syndromes...
  3. pmc Mutation spectrum of MLL2 in a cohort of Kabuki syndrome patients
    Lucia Micale
    Medical Genetics Unit, IRCCS Casa Sollievo della Sofferenza Hospital, 71013 San Giovanni Rotondo, Italy
    Orphanet J Rare Dis 6:38. 2011
    ..Recently mutations in the histone methyl transferase MLL2 gene have been identified as its underlying cause...
  4. ncbi Analyzing cell mechanics in hematologic diseases with microfluidic biophysical flow cytometry
    Michael J Rosenbluth
    Department of Bioengineering, 608B Stanley Hall, Berkeley, CA 94720 3220, USA
    Lab Chip 8:1062-70. 2008
    Pathological processes in hematologic diseases originate at the single-cell level, often making measurements on individual cells more clinically relevant than population averages from bulk analysis...
  5. ncbi Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
    Katherine K Matthay
    Department of Pediatrics, University of California at San Francisco, and UCSF Children s Hospital, San Francisco, CA 94143 0106, USA
    J Clin Oncol 25:1054-60. 2007
    ..To evaluate the effect of disease sites and prior therapy on response and toxicity after iodine-131-metaiodobenzylguanidine (131I-MIBG) treatment of patients with resistant neuroblastoma...
  6. pmc Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory
    Wanming Zhao
    Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA
    J Hematol Oncol 4:4. 2011
    ..This casts doubt on the primary role of JAK2V617F in the pathogenesis of MPNs and its diagnostic value...
  7. ncbi A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer
    John M Kirwan
    Liverpool Women s Hospital, Crown Street, Liverpool L78 7SS, UK
    Radiother Oncol 68:217-26. 2003
    ..Major concerns, however, remain over the acute and late toxicity and hence the generalisability of the conclusions of these studies...
  8. ncbi Mutations in SBDS are associated with Shwachman-Diamond syndrome
    Graeme R B Boocock
    Program in Genetics and Genomic Biology, Room 11 109A, Elm Wing Annex, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada
    Nat Genet 33:97-101. 2003
    ....
  9. pmc CD4+CD25highFoxP3+ regulatory T-cells in hematologic diseases
    Hee Won Moon
    Department of Laboratory Medicine, Konkuk University School of Medicine, Hospital, 4 12 Hwayang dong, Gwangjin gu, Seoul, Korea
    Korean J Lab Med 31:231-7. 2011
    ..We explored the status of Tregs in neoplastic and autoimmune hematologic diseases. We also evaluated the technical aspects of Treg measurement in terms of sample type and detection markers.
  10. ncbi Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival
    John E Wagner
    Blood and Marrow Transplant Program of the Department of Pediatrics, University of Minnesota Cancer Center and School of Medicine, Minneapolis 55455, USA
    Blood 100:1611-8. 2002
    ..7 x 10(5) CD34(+) cells per kilogram of recipient's body weight. Therefore, graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less...
  11. ncbi The clonogenic potential of hematopoietic stem cells and mesenchymal stromal cells in various hematologic diseases: a pilot study
    Meltem Kurt Yüksel
    Department of Hematology, Ankara Oncology Research and Education Hospital, Ankara University School of Medicine, Ankara, Turkey
    Cytotherapy 12:38-44. 2010
    ..that there should be a quantitative and qualitative relationship between MSC colonies (CFU-F) and hematopoietic stem cell colonies (colony-forming unit-granulocyte-macrophages; CFU-GM) among patients with and without hematologic diseases.
  12. ncbi Properties and potential of bone marrow mesenchymal stromal cells from children with hematologic diseases
    H Dimitriou
    Department of Pediatric Hematology Oncology, University Hospital of Heraklion University of Crete Medical School, Heraklion, Crete, Greece
    Cytotherapy 10:125-33. 2008
    ..As MSC constitute part of BM stroma, we examined their properties in children with hematologic diseases.
  13. ncbi Partial anomalous left pulmonary artery along with aortic coarctation in an infant with Kabuki syndrome
    Aarti H Bhat
    Division of Pediatric Cardiology, Seattle Children s Hospital, University of Washington, Seattle, Washington 98105, USA
    Echocardiography 29:E145-7. 2012
    ..While coarctation and hypoplastic left heart syndrome are observed in this syndrome, this is the second reported case of aLPA in KS and the first with the forme fruste of left-sided obstruction as well as aLPA in this group of patients...
  14. pmc Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation
    Tanyalak Parimon
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Am J Respir Crit Care Med 172:384-90. 2005
    ..The role of pulmonary function before stem cell transplant as a potential risk factor for the development of early post-transplant respiratory failure and mortality is controversial...
  15. ncbi Laparoscopic versus open splenectomy in the management of benign and malign hematologic diseases: a ten-year single-center experience
    Can Kucuk
    Department of General Surgery, Erciyes University School of Medicine, Kayseri, Turkey
    J Laparoendosc Adv Surg Tech A 15:135-9. 2005
    ..The aim of this study was to compare two cohorts of patients with similar characteristics, who underwent LS and OS in a single university teaching center...
  16. ncbi CAMPATH-1H in the treatment of autoimmune cytopenias
    J C Marsh
    Department of Haematology, St George's Hospital Medical School, London, UK
    Cytotherapy 3:189-95. 2001
    ..DISCUSSION: We conclude that Campath-1H can induce remissions in autoimmune cytopenias and we critically review its role in the treatment of these disorders...
  17. ncbi Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis
    S Schnittger
    Leukemia 22:453-5. 2008
  18. ncbi Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem cells in Chinese patients with hematologic diseases
    X Zhang
    Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
    Int J Lab Hematol 32:256-64. 2010
    ..MSCs and HSCs from the same human leukocyte antigen (HLA)-identical sibling donor in Chinese patients with hematologic diseases. Bone marrow mononuclear cells from healthy donors were cultured and expanded ex vivo...
  19. ncbi Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors
    Vanderson Rocha
    Department of Haematology, Eurocord Netcord EBMT office, Institut universitaire, Hopital Saint Louis, Universite de Paris 7, 1 av Claude Vellefaux, 75010 Paris, France
    Br J Haematol 147:262-74. 2009
    ..This review will focus on the interactions between HLA, cell dose and other modifiable factors related to the UCB unit selection and transplantation that may improve outcomes after UCB transplantation...
  20. ncbi Haematological profile of patients with pulmonary tuberculosis in Ibadan, Nigeria
    J A Olaniyi
    Department of Haematology, University College Hospital, Ibadan, Nigeria
    Afr J Med Med Sci 32:239-42. 2003
    ..6%, leucocytosis in 22.3%, neutrophilia in 45.2% and lymphopaenia in 4.8% of the patients. Thrombocytosis occurred in 12.9%,while 8% had thrombocytopaenia. None of the patients had leucopaenia and only 8.4% had lymphocytosis...
  21. ncbi Zebrafish as a model for vertebrate hematopoiesis
    Felix Ellett
    Cancer and Haematology Division, The Walter and Eliza Hall Institute for Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia
    Curr Opin Pharmacol 10:563-70. 2010
    ..This review highlights key recent studies that have used this model to provide insights into vertebrate hematopoietic development and innate immunity...
  22. pmc Strategies to enhance umbilical cord blood stem cell engraftment in adult patients
    Colleen Delaney
    Fred Hutchinson Cancer Research Center, Mailstop D2 100, 1100 Fairview Ave N, PO Box, 9024, Seattle, WA 98109, USA
    Expert Rev Hematol 3:273-83. 2010
    ..hematopoietic stem cells (HSCs) for allogeneic transplantation in children and adults in the treatment of hematologic diseases. However, compared with marrow or mobilized peripheral blood stem cell grafts from adult donors, ..
  23. ncbi Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors
    M J Laughlin
    Department of Medicine, Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, OH 44106 5065, USA
    N Engl J Med 344:1815-22. 2001
    ..We studied the use of transplantation of umbilical-cord blood to restore hematopoiesis in adults...
  24. pmc Zebrafish in hematology: sushi or science?
    Duncan Carradice
    Walter and Eliza Hall Institute of Medical Reserch, Department of Medical Biology, University of Melbourne, and Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Parkville, Australia
    Blood 111:3331-42. 2008
    ..Despite some limitations and challenges, their successes and discovery potential mean that zebrafish are here to stay in hematology research...
  25. ncbi Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases
    Naoyuki Uchida
    Department of Hematology, Toranomon Hospital, Tokyo, Japan
    Biol Blood Marrow Transplant 14:583-90. 2008
    Although allogeneic hematopoietic stem cell transplantation is a potentially curative approach for advanced hematologic diseases, its application to elderly people is limited because of their comorbid physical conditions and lower chance ..
  26. ncbi Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases
    Shigesaburo Miyakoshi
    Department of Hematology, Toranomon Hospital, Tokyo, Minato ku, Japan
    Transplantation 84:316-22. 2007
    ..Transplantation-related mortality (TRM) was 27% within 100 days. Therefore our objective was to evaluate the feasibility of RI-CBT with tacrolimus as GVHD prophylaxis for adult patients with hematologic malignancies...
  27. ncbi Modeling human hematopoietic and cardiovascular diseases in zebrafish
    Trista E North
    Division of Hematology Oncology, Department of Medicine, Children s Hospital of Boston, Enders Research Building, Boston, Massachusetts 02115, USA
    Dev Dyn 228:568-83. 2003
    ..This review aims to illustrate how the zebrafish has been used to identify unknown genes, to assign function to known genes, and to delineate genetic pathways, all contributing valuable leads toward understanding human pathophysiology...
  28. ncbi A comparison of the specificity and sensitivity of two Candida antigen assay systems for the diagnosis of deep candidiasis in patients with hematologic diseases
    Hirofumi Misaki
    Division of Transfusion Medicine, Fukui Medical University, Fukui, Japan
    Med Sci Monit 9:MT1-7. 2003
    ....
  29. ncbi Use of the zebrafish system to study primitive and definitive hematopoiesis
    Jill L O de Jong
    Stem Cell Program and Division of Hematology Oncology, Children s Hospital Boston and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Annu Rev Genet 39:481-501. 2005
    ....
  30. ncbi Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression
    Robert Z Orlowski
    Department of Medicine, Division of Hematology Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 25:3892-901. 2007
    ..This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma...
  31. ncbi Bone marrow necrosis: clinicopathologic analysis of 20 cases and review of the literature
    Semra Paydas
    Department of Oncology, Cukurova University Faculty of Medicine, Balcal, Adana, Turkey
    Am J Hematol 70:300-5. 2002
    ..In conclusion malignancy is the most common cause of BMN but some nonmalignant conditions such as tuberculosis and APS may be the underlying cause of BMN...
  32. ncbi Laparoscopic splenectomy for hematologic diseases: a preliminary analysis performed on the Italian Registry of Laparoscopic Surgery of the Spleen (IRLSS)
    M Casaccia
    Advanced Laparoscopic Unit, Department of General Surgery and Transplant, San Martino University Hospital, University of Genoa, Monoblocco IV Piano, Largo R Benzi 10, 16132, Genoa, Italy
    Surg Endosc 20:1214-20. 2006
    ..In this first study analyzing the IRLSS data, a cohort of patients with hematologic diseases was retrospectively investigated for potential predictive parameters that could affect the outcome of ..
  33. ncbi Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan
    Masahiro Imamura
    Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Int J Hematol 83:164-78. 2006
    ..OS for each disease was analyzed by patient age, stem cell source, donor type, disease status, and disease type. These data provide objective and valuable information for hematologists as well as for patients who need HCT...
  34. ncbi Recovery after stem-cell transplantation for hematologic diseases
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:242-52. 2001
    ....
  35. ncbi Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases
    Johan Maertens
    Department of Hematology, Medical Intensive Care Unit, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Infect Dis 49:1688-93. 2009
    ..Galactomannan (GM) detection in bronchoalveolar lavage (BAL) fluid by the Platelia enzyme immunoassay aims to further improve upon the test's utility by applying it directly to specimens from the target organ...
  36. ncbi Association of transforming growth factor-beta1 gene polymorphism in the development of Epstein-Barr virus-related hematologic diseases
    Kanako Hatta
    Department of Pediatrics, Kyoto Prefectural University of Medicine, Kawaramachi, Hirokoji, Kamigyo ku, Kyoto, Japan
    Haematologica 92:1470-4. 2007
    ..In this study, the pattern of cytokine gene polymorphisms was comparatively analyzed in EBV-related diseases...
  37. ncbi 101 laparoscopic splenectomies for the treatment of benign and malignant hematologic disorders
    Eric M Knauer
    Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston VA Medical Center, Houston, TX, USA
    Am J Surg 186:500-4. 2003
    ..Patients with idiopathic thrombocytopenic purpura (ITP) have normal to slightly enlarged spleens and benefit the most from LS...
  38. ncbi Application of the molecular analysis of the T-cell receptor repertoire in the study of immune-mediated hematologic diseases
    Magdalena Plasilova
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, R40, USA
    Hematology 8:173-81. 2003
    ..and the detection of immunodominant clonotypes represents a novel approach in the study of immune-mediated hematologic diseases, such as aplastic anemia (AA), some forms of myelodysplasia (MDS), anti-leukemic immune surveillance, graft-..
  39. ncbi Rituximab in autoimmune hematologic diseases: not just a matter of B cells
    Roberto Stasi
    Department of Haematology, St George s Hospital, London, United Kingdom
    Semin Hematol 47:170-9. 2010
    ..results in immune thrombocytopenia (ITP), the use of this agent was explored in other autoimmune hematologic diseases, most notably autoimmune hemolytic anemia (AIHA) and thrombotic thrombocytopenic purpura (TTP), ..
  40. ncbi Application of nucleic acid sequence-based amplification for diagnosis of and monitoring the clinical course of invasive aspergillosis in patients with hematologic diseases
    Jin Hong Yoo
    Department of Internal Medicine, Division of Infectious Diseases, The Catholic Hematopoietic Stem Cell Transplantation Center, The Catholic University of Korea College of Medicine, Seoul, South Korea
    Clin Infect Dis 40:392-8. 2005
    ..Blood samples were collected twice per week from 128 patients with hematologic diseases during periods of neutropenic fever after undergoing chemotherapy or hematopoietic stem cell ..
  41. ncbi Therapeutic granulocyte transfusions for the treatment of febrile neutropenia in patients with hematologic diseases: a 10-year experience at a single institute
    Ki Hwan Kim
    Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
    Cytotherapy 13:490-8. 2011
    ....
  42. ncbi A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty
    Gina Zini
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
    Br J Haematol 151:359-64. 2010
    ..Moreover, this collective work resulted in the production of a consensus statement, taking into account individual practices, collegial agreement and literature data...
  43. ncbi Handheld gamma probe used to detect accessory spleens during initial laparoscopic splenectomies
    Umut Barbaros
    Department of General Surgery, Istanbul University, Istanbul Medical School, Capa, 34390, Istanbul, Turkey
    Surg Endosc 21:115-9. 2007
    ..This study aimed to evaluate the practicability and efficacy of a handheld gamma probe in identifying accessory spleens at the initial intervention...
  44. ncbi Targeting the RAS signaling pathway in malignant hematologic diseases
    M A Morgan
    Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, Carl Neuberg Str 1, D 30625 Hannover, Germany
    Curr Drug Targets 8:217-35. 2007
    ..This review provides a background on RAS signaling in hematologic malignancies and discusses opportunities to exploit aberrant cancer cell signaling in order to develop better treatment options for patients suffering from these diseases...
  45. ncbi Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy
    Jann Yuan Wang
    Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
    Ann Thorac Surg 78:267-72. 2004
    ..We analyzed the etiologies and prognostic factors in bone marrow recipients with diffuse pulmonary infiltrates and assessed the role of open lung biopsy in managing this complication...
  46. ncbi The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone
    Faith E Davies
    Haematologica 92:1149-50. 2007
    ..The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups...
  47. pmc Candida krusei transmission among hematology patients resolved by adapted antifungal prophylaxis and infection control measures
    Margreet C Vos
    Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Microbiol 44:1111-4. 2006
    ..We intervened by changing antifungal prophylaxis and implementing strict infection control measures. The incidence dropped immediately...
  48. ncbi Portal vein thrombosis following splenectomy: identification of risk factors
    Fumihiko Fujita
    Center for Minimally Invasive Surgery, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Am Surg 69:951-6. 2003
    ..Six hundred eighty-eight patients underwent splenectomy during this period, 321 of them for hematologic diseases. Eleven of the 688 patients had PVT associated with splenectomy, and the charts of these patients were ..
  49. ncbi Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
    E Van Cutsem
    University Hospital Gasthuisberg, Department of Internal Medicine, Leuven, Belgium
    Eur J Cancer 35:54-9. 1999
    ..The toxicity profile of CPT-11 is becoming better understood and has been considerably improved...
  50. ncbi Clinical and quality of life outcomes of laparoscopic and open splenectomy for haematological diseases
    V Velanovich
    Divisions of General Surgery and Hematology/Oncology, Henry Ford Hospital, Detroit, Michigan 48202-2689, USA
    Eur J Surg 167:23-8. 2001
    ..CONCLUSION: In properly selected patients laparoscopic splenectomy is preferable to open splenectomy...
  51. ncbi Outcome of laparoscopic splenectomy for malignant hematologic diseases
    Davide Cavaliere
    Divisione di Chirurgia Generale e Trapianti d Organo, Genoa, Italy
    Tumori 90:229-32. 2004
    ..The aim of this study was to assess whether the benign or malignant nature of hematological diseases may influence the outcome of laparoscopic splenectomy...
  52. ncbi Zebrafish as a model of human hematologic disorders
    Ebrahim Shafizadeh
    Division of Hematology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Curr Opin Hematol 11:255-61. 2004
    ....
  53. ncbi Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation
    I W Blau
    Medizinische Klinik III Hämatologie, Onkologie und Transfusionsmedizin, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Hematol 86:583-9. 2007
    ..We conclude that reduced-intensity conditioning with fludarabine and treosulfan before allogeneic SCT is myeloablative, provides stable engraftment, and leads to complete chimerism in the majority of patients...
  54. ncbi Initial chemotherapy in gliomatosis cerebri
    M Sanson
    Fédération de Neurologie Mazarin, Groupe hospitalier Pitié Salpêtrière and Université Pierre et Marie Curie, Paris, France
    Neurology 63:270-5. 2004
    ..Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity. In this setting, initial chemotherapy warrants further investigation...
  55. ncbi Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico
    Oscar Gonzalez Llano
    Pediatric Department and Hematology Service, School of Medicine and University Hospital, Dr Jose E Gonzalez, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico
    Pediatr Hematol Oncol 25:39-47. 2008
    ..A reduced-intensity conditioning regimen including fludarabine, cyclophosphamide, and melphalan was administrated. Three patients are disease-free transplant survivors without graft-versus-host disease after 46, 34, and 16 months...
  56. ncbi Graft versus host disease in allogeneic stem cell transplantation--3 1/2 years experience
    KhalilUllah Hashmi
    Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
    J Pak Med Assoc 55:423-7. 2005
    ..To evaluate the frequency and outcome of graft versus host disease after allogeneic stem cell transplant in haematological disorders at Armed Forces Bone Marrow Transplant Centre, Rawalpindi from July 2001 to December 2004...
  57. pmc Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation
    Bipin N Savani
    Hematology Branch, National Heart, Lung and Blood, National Institutes of Health, Bethesda, Maryland 20892 1202, USA
    Biol Blood Marrow Transplant 12:1261-9. 2006
    Pulmonary function (PF) was studied in 69 consecutive patients with hematologic diseases, with a minimum 5-year (range, 5-13 years) follow-up after allogeneic stem cell transplantation from an HLA-matched sibling...
  58. ncbi Impact of CD31 mismatches on the outcome of hematopoeitic stem cell transplant of HLA-identical sibling
    Farha A el-Chennawi
    Clinical Immunology Unit, Clinical Pathology Department, Mansoura Faculty of Medicine, Mansoura, Egypt
    Hematology 11:227-34. 2006
    ..014 and OR = 4.21). In conclusion, the donor-recipient CD31 nonidentity is a significant risk factor for aGVHD and relapse in HLA-identical sibling...
  59. ncbi Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial
    Xavier Thomas
    Service d Hematologie, Hopital Edouard Herriot, 69437, Lyon Cedex 03, France
    Ann Hematol 84:376-82. 2005
    ..CR proportion was significantly higher in patients with a first CR duration > or =6 months when compared with those from a control trial using standard-dose mitoxantrone (90 vs 70%, p=0.03)...
  60. ncbi Molecular analysis of T-cell repertoire in patients with graft-versus-host disease after allogeneic stem cell transplantation
    Yutaka Tsutsumi
    Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Leuk Lymphoma 45:481-8. 2004
    ..0055). These results suggest that we might be able to consider a possible development of cGVHD by analyzing TCR-VB spectratyping after allo-SCT...
  61. ncbi ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis
    G Martinelli
    Division of Hematology Oncology, European Institute of Oncology, Milan, Italy
    Br J Haematol 125:584-9. 2004
    ..Long-term results of the ongoing randomized trial, comparing ABVD versus high-dose intensity weekly regimens will be useful to confirm our results...
  62. ncbi A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer
    David M Friedland
    US Oncology, Inc, Houston, Texas, USA
    Cancer Invest 22:374-82. 2004
    ..This regimen warrants further study, perhaps as a three out of four week regimen or at reduced doses...
  63. ncbi Life-threatening neurological complications after bone marrow transplantation in children
    D Uckan
    Department of Pediatrics, Units of Bone Marrow Transplantation and Hematology, Hacettepe University Faculty of Medicine, Children s Hospital, Yenisehir, Ankara 06100, Turkey
    Bone Marrow Transplant 35:71-6. 2005
    ....
  64. ncbi Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma
    Gloria J Morris
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Haematologica 89:1484-91. 2004
    ..We designed a phase II trial of alternating fludarabine and IFNalpha2a to determine response rate, time to progression and toxicity of this regimen in patients with advanced stage low-grade NHL or mantle cell lymphoma...
  65. ncbi Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome
    R Nakamura
    Division of Hematology Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Bone Marrow Transplant 40:843-50. 2007
    ..5 versus 7%, P=0.02). RIC with fludarabine plus melphalan was associated with durable disease control and acceptable toxicity in this high-risk cohort...
  66. ncbi Sibling donor cord blood transplantation for thalassemia major: Experience of the Sibling Donor Cord Blood Program
    Mark C Walters
    Children s Hospital and Research Center at Oakland, 747 52nd St, Oakland, CA 94609, USA
    Ann N Y Acad Sci 1054:206-13. 2005
    ..It was concluded that cord blood transplantation from sibling donors represents a suitable alternative to bone marrow transplantation...
  67. ncbi Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience
    J N Berman
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 37:73-80. 2006
    ..034, respectively) in allogeneic patients. Consideration of HZ infection particularly in patients >10 years of age with elevated ALT after TBI-conditioned allogeneic HSCT may permit earlier diagnosis and therapeutic intervention...
  68. ncbi Increased acute GvHD and higher transplant-related mortality in non-caucasians undergoing standard sibling allogeneic stem cell transplantation
    M Karanth
    Bone Marrow Transplant Unit, University Hospital Birmingham NHS Trust, Birmingham, UK
    Bone Marrow Transplant 37:419-23. 2006
    ....
  69. ncbi Haematopoietic stem cell transplantation for Shwachman-Diamond disease: a study from the European Group for blood and marrow transplantation
    Simone Cesaro
    Department of Pediatrics, Clinic of Paediatric Haematology Oncology, University of Padova, Italy
    Br J Haematol 131:231-6. 2005
    ..Further improvements would be anticipated by a better definition of the optimum time in the course of disease to transplant and by the adoption of less toxic conditioning regimens...
  70. ncbi Significance of eosinophilia after stem cell transplantation as a possible prognostic marker for favorable outcome
    T Sato
    Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan
    Bone Marrow Transplant 36:985-91. 2005
    ..The reasons for this good prognosis in SCT patients with eosinophilia are discussed...
  71. ncbi Helicobacter pylori as cause of gastrointestinal disease in children with hemato-oncologic diseases
    Elio Castagnola
    Infectious Diseases Unit, G Gaslini Children s Hospital, Genoa, Italy
    Pediatr Blood Cancer 47:89-91. 2006
    ..pylori faecal antigen. All patients recovered with appropriate therapy. H. pylori may represent a cause of severe gastrointestinal complications in children with cancer or following bone marrow transplant...
  72. ncbi Clinical characteristics and treatment results of pediatric B-cell non-Hodgkin lymphoma patients in a single center
    Ceyda Karadeniz
    Gazi University Faculty of Medicine, Department of Pediatric Oncology, Ankara, Turkey
    Pediatr Hematol Oncol 24:417-30. 2007
    ..By multivariate analysis only LDH level was significant. In conclusion, the treatment results in this study were similar to those of BFM group...
  73. ncbi Allogeneic hematopoietic stem cell transplantation--yesterday, today, and tomorrow
    Rainer Storb
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109, USA
    Exp Hematol 31:1-10. 2003
    ..into the use of hematopoietic stem cell transplantation (HSCT) for therapy of cancer and nonmalignant hematologic diseases have changed this treatment modality from one that was thought to be plagued by insurmountable ..
  74. ncbi Post-transplant infections: single center experience from the developing world
    Khalil Ullah
    Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan
    Int J Infect Dis 12:203-14. 2008
    ..To describe our experience of post-transplant infections in allogeneic stem cell transplants at the Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan...
  75. ncbi [Non-myeloablative transplant of hematopoietic precursor cells. Myth and reality]
    David Gomez-Almaguer
    Servicio de Hematologia, Hospital Universitario de la UANL Dr José E González, Monterrey, NL
    Rev Invest Clin 57:291-7. 2005
    ..This kind of transplant is making real progress in the world of transplantation...
  76. ncbi Adjuvant treatment of high-risk adult soft tissue sarcomas: a survey by the Italian Sarcoma Group
    Sergio Frustaci
    Department of Medical Oncology, National Cancer Institute, Aviano
    Tumori 92:92-7. 2006
    ..The aim of this study was to test the protocol reproducibility when applied as a standard practice...
  77. ncbi Differential diagnosis of cholestasis following allogeneic hematopoietic stem cell transplantation in children: the contribution of serum bile acid levels in relation to other liver function tests
    J L Zakrzewski
    University Hospitals of Essen, Department of Pediatric Hematology, Oncology and Endocrinology, Essen, Germany
    Pediatr Hematol Oncol 21:697-705. 2004
    ..For cholestasis in absence of hepatic GvHD bile acid seems to be more sensitive than bilirubin. Routinely monitoring of bile acid after hematopoietic stem cell transplantation is not indicated...
  78. ncbi Impact of ABO incompatibility on outcome after allogeneic peripheral blood stem cell transplantation
    J G Kim
    Department of Hematology Oncology, Kyungpook National University Hospital, Daegu, Korea
    Bone Marrow Transplant 35:489-95. 2005
    ....
  79. ncbi Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors
    Sabine Wagner
    Department of Pediatric Oncology, Krankenhaus der Barmherzigen Bruder, Klinik St Hedwig, Steinmetzstrasse 1 3, Regensburg, Germany
    J Neurooncol 86:175-81. 2008
    ..To confirm the effectiveness of this treatment combination and determine its possible toxicity, we conducted a retrospective review of the charts of children who received the therapy...
  80. ncbi Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study
    Amnon Cohen
    Department of Pediatrics, University of Genova, Polo del Ponente, San Paolo Hospital, Savona, Italy
    J Clin Oncol 25:2449-54. 2007
    ..This study evaluates the incidence and the risk factors contributing to secondary thyroid carcinoma (STC) in patients who receive transplantation...
  81. ncbi A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients
    Ifeyinwa Osunkwo
    Department of Pediatrics, Children s Hospital of New York Presbyterian, Columbia University, New York, New York, USA
    Biol Blood Marrow Transplant 10:246-58. 2004
    ..Further pharmacokinetic and pharmacodynamic studies are ongoing in pediatric and adolescent AlloSCT recipients to define optimal MMF dosing...
  82. ncbi Allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical sibling donors in children with hematological diseases: a single center pilot study
    A I Benito
    Department of Pediatrics, Division of Pediatric Hematology/Oncology, , Madrid, Spain
    Bone Marrow Transplant 28:537-43. 2001
    ..Studies including larger numbers of pediatric patients undergoing allogeneic PBSCT are warranted to determine the long-term outcomes of such procedures...
  83. ncbi Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200
    Aloysius Y L Ho
    Blood 101:779-80. 2003
  84. ncbi Severe neurologic complications after hematopoietic stem cell transplantation in children
    M Faraci
    Department of Hematology Oncology, Bone Marrow Transplant Unit, G Gaslini Children s Research Institute, Genova, Italy
    Neurology 59:1895-904. 2002
    ..To describe and evaluate the incidence and risk factors of severe neurologic events (SNE) in pediatric recipients of allogeneic or autologous hematopoietic stem cell transplantation (HSCT) for hematologic or nonhematologic diseases...
  85. ncbi EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation
    A Davidson
    Children s Department, Royal Marsden NHS Trust Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
    Eur J Cancer 38:2422-7. 2002
    ..We conclude that this combination is tolerable in heavily pretreated patients and may be suitable for further evaluation in untreated poor risk tumours...
  86. ncbi Allogeneic peripheral blood stem cell transplantations in children--a single center experience
    S Sufliarska
    Bone Marrow Transplantation Unit, Department of Pediatrics, Comenius University Medical School, Bratislava, Slovak Republic
    Neoplasma 51:110-6. 2004
    ..It is associated with rapid engraftment, no greater incidence of acute but a higher incidence of chronic GVHD as compared to bone marrow transplantation (BMT) and therefore suitable mainly for children suffering from malignant diseases...
  87. ncbi Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation
    N Worel
    Department of Medicine I, Bone Marrow Transplantation Unit, University of Vienna, Austria
    Bone Marrow Transplant 30:619-26. 2002
    ..These results from long-term survivors show that high cure rates with good to very good QoL can be achieved by allogeneic or syngeneic SCT...
  88. ncbi Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin
    M Ortin
    The Bone Marrow Transplant Unit, Department of Haematology and Oncology, The Birmingham Children s Hospital, UK
    Bone Marrow Transplant 30:359-66. 2002
    ..We conclude that partially matched related donors are a feasible source of haemopoietic progenitor cells for transplantation for patients without matched familial or unrelated donors...
  89. ncbi Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations
    Sharon R Lewin
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY
    Blood 100:2235-42. 2002
    ..T-cell neogenesis, appropriate to age but delayed in adult recipients of T-cell-depleted allografts, justifies interventions to hasten this process and to stimulate desirable cellular immune responses...
  90. ncbi Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation
    J S McCune
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Bone Marrow Transplant 30:167-73. 2002
    ..It may be possible to improve the outcome of HSCT in pediatric patients receiving the BU/CY regimen through optimization of busulfan C(SS) and better definition of the contribution of activated cyclophosphamide metabolites to toxicity...
  91. ncbi Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease
    S Kumar
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Bone Marrow Transplant 30:161-5. 2002
    ..03). Relapse-free survival was similar for the two groups. We conclude that omitting day +11 MTX appears to increase the risk of severe acute GVHD...
  92. ncbi Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome
    Marco Zecca
    Oncoematologia Pediatrica, Universita di Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
    Blood 100:1192-200. 2002
    ..Use of CB stem cells and preparative regimens without radiotherapy may prevent its development. In patients affected by ALL, cGVHD was associated with a strong graft-versus-leukemia effect, improving DFS...
  93. ncbi Tecelac as antithymocyte globulin in conditioning for childhood allogeneic stem cell transplantation
    S Y Zimmermann
    Department of Pediatric Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
    Bone Marrow Transplant 29:957-62. 2002
    ..Viremia occurred in two, with no viral disease developed. Of the eight patients surviving, one suffered relapse of acute leukemia, one shows impending graft failure. The others are well. Using RATG in conditioning is feasible...
  94. pmc Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours
    K Fizazi
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Br J Cancer 86:1555-60. 2002
    ..Because outcomes with this regimen compare favourably with outcome after standard therapy, dose-dense chemotherapy should be further investigated in this subset of patients...
  95. ncbi Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone
    Sibel Koc
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 100:48-51. 2002
    ....
  96. ncbi Burkitt's lymphoma: single-centre experience with modified BFM protocol
    E Harris
    Department of Haematology, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK
    Clin Lab Haematol 24:111-4. 2002
    ..Two patients relapsed, one 24 months post-BFM chemotherapy and the other 1-month post-autologous stem cell transplantation and 2 months post-BFM chemotherapy...
  97. pmc Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
    Chunkang Chang
    Department of Hematology, Shanghai Sixth People s Hospital, Shanghai Jiaotong University, Shanghai, People s Republic of China
    Blood 110:1379-87. 2007
    ..The data suggest that overall inferior outcome in patients with secondary MDS/tAML was related to the frequency of high-risk cytogenetics. For both cohorts, transplantation outcomes improved over the time interval studied...
  98. ncbi HLA-identical sibling peripheral blood stem cell transplantation in children and adolescents
    Tsutomu Watanabe
    Department of Pediatrics, University of Tokushima School of Medicine, Japan
    Biol Blood Marrow Transplant 8:26-31. 2002
    ..For high-risk malignancies, whether or not a graft-versus-leukemia effect prevents relapse needs to be clarified in future comparative studies with BMT...
  99. ncbi The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients
    Ugo De Giorgi
    Department of Oncology and Hematology, Santa Maria delle Croci Hospital, Viale Randi 5, 48100 Ravenna, Italy
    Haematologica 87:95-104. 2002
    ..This paper presents an update of available information in order to define the status of HDCT in GCT patients...
  100. ncbi Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer
    F Puglisi
    Department of Clinical Oncology, University Hospital of Udine, Piazzale S M Misericordia, 33100 Udine, Italy
    Ann Oncol 19:1541-6. 2008
    ..Furthermore, we explored the relationship between TP tumor expression and benefit from this regimen...
  101. ncbi Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect
    Emiko Sakaida
    Division of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Inohana 1 8 1, Chuo Ku, Chiba City, Chiba, 260 8670, Japan
    Blood 102:4236-42. 2003
    ..9%] versus 16 of 52 [30.8%]; P =.0387). These results indicate that the development of LONIPCs was strongly associated with chronic GVHD and especially with sicca syndrome and the graft-versus-leukemia (GVL) effect...

Research Grants62

  1. Molecular Mechanisms of Parvovirus Gene Expression and Replication
    Jianming Qiu; Fiscal Year: 2013
    ..e., EPCs ex vivo-expanded under hypoxic conditions for B19V in this application. ..
  2. Pluripotent stem cell-derived HSCs: improvements and molecular mechanisms
    Patrick Cahan; Fiscal Year: 2013
    ..An extensive program of formal training, course-work, meetings with the advisory committee, and dedicated supervision and mentorship by Dr. Daley will ensure that these goals are achieved. ..
  3. PRE- AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGY
    J Evan Sadler; Fiscal Year: 2013
    ..advances in hematology have led the way in many fields of basic and translational biomedical research, hematologic diseases remain major threats to public health...
  4. Novel Hematopoietic Conditioning Agents for Treatment of Hematological Diseases
    Olga B Chernova; Fiscal Year: 2010
    ..The development of hematopoietic-specific conditioning agents should provide a less toxic alternative to current regimens and, thus, has major implications for patients receiving HSCT for the treatment of hematological diseases. ..
  5. Non-viral gene therapy for sickle cell anemia
    CLIFFORD JOHN STEER; Fiscal Year: 2012
    ..The ultimate goal of this research project is to develop and evaluate in patients an innovative gene therapy approach that has the potential to treat and correct SCA. ..
  6. Transplantation tolerance and immune function following mTOR inhibition.
    Jonathan D Powell; Fiscal Year: 2013
    ..It is hoped that the results of this study will allow safer application of this curative therapy to a greater number of patients and aid in improving tolerogenic therapy for autoimmunity and solid organ transplantation as well. ..
  7. Role of FA proteins in hematopoiesis
    Qishen Pang; Fiscal Year: 2013
    ..The proposed study will provide valuable information for therapeutic prevention and treatment of bone marrow failure and cancer progression of not only FA but also other blood diseases. ..
  8. Genetic and Epigenetic Regulation of Hematopoiesis.
    Shireen Saleque; Fiscal Year: 2013
    ..Elucidating the normal functions of these proteins and their collaborators in blood cell production will also uncover the latent malignant properties of these genes. ..
  9. Zebrafish Genetics to Identify Genes Involved in Hematopoiesis
    DHVANIT INDRAVADAN SHAH; Fiscal Year: 2013
    ..analyses, we hypothesized that the genetic screens for anemic mutants are not at saturation to study hematologic diseases. We employed de novo ethyl nitrosourea (ENU) based genetic screens and identified five unique zebrafish ..
  10. Role of Vav and Rac in KIT oncogenesis
    Reuben Kapur; Fiscal Year: 2013
    ..in contrast to successful use of Gleevec to treat GISTs, Gleevec is ineffective for the treatment of the hematologic diseases harboring the KIT activation loop mutants (i.e. KITD816V), including SM and CBF- AML...
  11. Processing and Preservation of Human Umbilical Cord Stem Cells for Cell Therapeut
    Alfred Bahnson; Fiscal Year: 2010
    ..5000 allogeneic cord blood (UCB) transplantations have been reported to treat both adults and children with hematologic diseases (1-5)...
  12. Phase II Trial of Vorinostat plus Tacrolimus and Mycophenolate to Prevent GVHD
    Sung Choi; Fiscal Year: 2013
    ..Allogeneic BMT is a potentially curative therapy for many non-hematologic and hematologic diseases. Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic BMT and ..
  13. Effect of anti-S phase agents on human chromosomes
    Anindya Dutta; Fiscal Year: 2013
    ..Finally, we will examine which, where and in what order checkpoint activators and DNA repair proteins are recruited to the stalled replication forks created by anti-S phase agents. ..
  14. Testing the safety and efficacy of inhibitory RNA mediated purine analog resistan
    Christopher C Porter; Fiscal Year: 2010
    ..A variety of human hematologic diseases would benefit from this strategy of in vivo cell selection, including, but not limited to congenital bone ..
  15. Training program in hematologic and oncologic diseases
    Yi Zheng; Fiscal Year: 2012
    ..The areas of research include pediatric hematologic diseases such as leukemia, Fanconi anemia, myeloproliferative disorders, coagulation disorders, and sickle cell ..
  16. Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques
    Leslie S Kean; Fiscal Year: 2013
    ..transplantation (BMT) represents the best chance for cure for a large number of malignant and non-malignant hematologic diseases. However, BMT implementation is currently limited by the many critical complications that accompany this ..
  17. Novel Mechanisms of C-Kit Regulation in Mast Cells
    Reuben Kapur; Fiscal Year: 2013
    ..provided by applicant): Myeloproliferative neoplasms or MPNs are a heterogeneous group of complex hematologic diseases, which share the common characteristic of myeloid cell overproduction...
  18. Stem Cell Transplantation in 2020: A Workforce and Infrastructure Assessment
    Edward Snyder; Fiscal Year: 2011
    ..stem-cell transplantation (HSCT) is the only known curative therapy for many patients with life-threatening hematologic diseases. More than 20,000 HSCT are performed in the United States yearly and the need for HSCT is expected to ..
  19. Sleeping Beauty-mediated Gene Therapy of X-linked SCID
    Kendra A Hyland; Fiscal Year: 2010
    ..In addition, it will provide the basis for the development of the SB transposon system for treatment of other hematologic diseases.
  20. 2012 CRTI Summer Workshop
    Mark Crowther; Fiscal Year: 2012
    ....
  21. Cincinnati Center for Excellence in Molecular Hematology
    Yi Zheng; Fiscal Year: 2013
    ..and sorting capabilities, a Genomics &Genetics Core that support cutting edge genomic analysis of hematologic diseases and normal genetic traits of stem/progenitor cells, and a Translational Core that covers services such as ..
  22. Conformal Total Body and Marrow Irradiation for Leukemia
    Susanta K Hui; Fiscal Year: 2013
    ..control and thus, is expected to have a significant impact on patients with advanced leukemia and other hematologic diseases. Adaptive TBMI has the potential for better disease control, reduced disease recurrence and increased ..
  23. Nucleophosmin and ribosomal dysfunction in hematologic diseases
    Pier Paolo Pandolfi; Fiscal Year: 2010
    ..We expect that this project will contribute a significant advancement to our understanding of MDS and other hematologic disorders characterized by strong anemia and dyserythropoiesis thereby having a positive impact on human health. ..
  24. The Atrial Fibrillation - Factor Identification to Risk Modification Study in HD
    WOLFGANG CHRISTOPH WINKELMAYER; Fiscal Year: 2013
    ..of Diabetes and Digestive and Kidney Diseases, and more specifically the Division of Kidney, Urologic, and Hematologic Diseases, which will consider this application for funding...
  25. Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT)
    Stephanie J Lee; Fiscal Year: 2013
    ..States, primarily for the treatment of rare diseases such as leukemia, lymphoma, multiple myeloma and other hematologic diseases. Approximately 50% of allogeneic HCT recipients develop immune mediated disorders resulting in high ..
  26. Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplants (HCT)
    Stephanie J Lee; Fiscal Year: 2010
    ..States, primarily for the treatment of rare diseases such as leukemia, lymphoma, multiple myeloma and other hematologic diseases. Approximately 50% of allogeneic HCT recipients develop immune mediated disorders resulting in high ..
  27. Role of noncoding RNA in Regulating GVHD
    Pavan Reddy; Fiscal Year: 2013
    ..Such an approach may prove to be beneficial in a broad array of many other T cell mediated immune diseases. ..
  28. Supplementation of cord blood transplants with limphoid progenitors
    Britte C Beaudette Zlatanova; Fiscal Year: 2010
    ..We anticipate that achievement of this goal will reduce mortality due to post-transplant infection and make cord blood transplants available to patients of all ages, ethnicities, and both genders. ..
  29. Macrophage Regulation of the Hematopoietic Stem Cell Niche
    JONATHAN GEORGE HOGGATT; Fiscal Year: 2013
    ..stem cell transplantation is currently the only curative treatment modality for a number of malignant hematologic diseases. Yet, despite this fact, transplant related morbidity and mortality remains high, and only a fraction of ..
  30. Training in Developmental Hematology
    Donald B Kohn; Fiscal Year: 2013
    ..Very little is understood about the molecular pathogenesis of many of the hematologic diseases in children...
  31. Molecular Events Initiating B Cell Fate Determination
    KAY LYNN MEDINA; Fiscal Year: 2013
    ..the normal B cell developmental pathway will provide insight into the molecular and cellular basis of many hematologic diseases. Although considerable progress has been made in understanding the generation of naive B cells from ..
  32. The Role of N-Cadherin in the Regulation of the Hematopoietic Stem Cell Niche
    ADAM MICHAEL GREENBAUM; Fiscal Year: 2012
    ..By further understanding how hematopoietic stem cells are regulated by the cells which surround them, we hope to better understand the pathogenesis of hematological diseases. ..
  33. Cytokine Induced CD26 Modulation of Adult Hematopoietic Stem Cell Trafficking
    Kent Christopherson; Fiscal Year: 2009
    ..stem cell transplantation (HSCT) is a successful treatment option for many patients with severe hematologic diseases. However, large numbers of transplantable cells are needed and patient survival is compromised when donor ..
  34. Targeting BAX Oligomerization in Hematologic Disease
    Evripidis Gavathiotis; Fiscal Year: 2010
    ..between cellular life and death and, when deregulated, contributes to the pathogenesis of a wide variety of hematologic diseases characterized by too many or too few blood cells...
  35. Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
    JING RUEY JOANNA YEH; Fiscal Year: 2012
    ..Ultimately, this program will facilitate the candidate's goals of becoming an independent investigator in cancer and aging. ..
  36. Specificity of the Ubiquitin System in Lymphoid Malignancies
    Luca Busino; Fiscal Year: 2013
    ..Here we propose to study the role of Fbxw7 in hematologic diseases. Fbxw7 (F-box/WD40 repeat-containing protein 7) is a member of the F-box family of proteins that functions ..
  37. Research Initiatives for the Preventions of Complications of Thalassemia
    THOMAS DUANE COATES; Fiscal Year: 2011
    ..Information from this system will be used by the Hematologic Diseases Branch of CDC to assess the safety of the blood supply and to develop and monitor the effectiveness of ..
  38. An Oxygen-Sensing Network Involving Heme and Chaperones
    Li Zhang; Fiscal Year: 2009
    ..The gained knowledge should facilitate the understanding of the molecular mechanisms of oxygen sensing, heme signaling and chaperone action in higher eukaryotes. ..
  39. The role of HDAC1 acetylation on corepressor complex activity and hematopoiesis
    Yi Qiu; Fiscal Year: 2013
    ..Misregulation of GATA-1 is linked to hematologic diseases including leukemia...
  40. Comparative Effectiveness and Safety of Newer Agents for Anemia Treatment in HD
    WOLFGANG CHRISTOPH WINKELMAYER; Fiscal Year: 2013
    ..congruence with the mission of the National Institutes of Diabetes and Digestive and Kidney Diseases, and more specifically the Division of Kidney, Urologic, and Hematologic Diseases, which will consider this application for funding.
  41. Zfx, A Novel Transcriptional Regulator of Hematopoiesis
    Boris Reizis; Fiscal Year: 2013
    ..We have identified a novel gene, Zfx, which appears important for leukemia development and propagation. Studies on the role and mechanism of action of Zfx in leukemia may provide novel therapeutic approaches to the disease. ..
  42. DANGER: Developing the Next Generation of Emergency Medicine Researchers
    Nathan Kuppermann; Fiscal Year: 2013
    ....
  43. mTOR Complexes in Hematopoiesis
    Demetrios Kalaitzidis; Fiscal Year: 2013
    ..The Department of Hematology/Oncology at CHB, with its world-class resources and critical mass of researchers, is ideally suited for this career- development proposal to be executed. ..
  44. APS STEP-UP: Promoting Diversity Through Research Experiences and Professional So
    Marsha Lakes Matyas; Fiscal Year: 2013
    ..areas (diabetes, endocrinology, metabolism, nutrition, obesity, and digestive, liver, urologic, kidney, and hematologic diseases)...
  45. Eperimental Hemaotology-Immunology
    David E Harrison; Fiscal Year: 2012
    ..The primary training facility is TJL, a private, independent research center. TJL is an NIH Basic Cancer Research Center, raises 3 million mice annually, and has held NIH research training grants since 1956. ..
  46. Minority Institution Research Training Program
    Samuel E Adunyah; Fiscal Year: 2013
    ..End of Abstract) ..
  47. Short Term Research Training for Health Professional Students
    Leonard E Egede; Fiscal Year: 2013
    ..endocrine disorders, as well as the biology and pathophysiology of kidney, digestive, urologic and hematologic diseases. The program provides a 10-12 week research project, under the supervision of an established investigator, ..
  48. MAPPING AND CLONING TRANSLOCATION BREAKPOINTS
    Janet Rowley; Fiscal Year: 2004
    ..These three genes are very important in human acute leukemia as well as in other hematologic diseases. They have been shown to be involved in translocations with many other genes...
  49. Bone Marrow Transplantation in Human Disease
    Richard J Jones; Fiscal Year: 2013
    ..allows safe and effective mismatched BMT, making AlloBMT a feasible alternative for severe non-malignant hematologic diseases and allowing donor selection based on genetic factors other than HLA, 2)improved immunologic recovery after ..
  50. Impact of Comorbidities on Outcomes of Allogeneic Transplantation
    Mohamed Sorror; Fiscal Year: 2013
    ..abstract_text> ..
  51. Clinical Trials Development Resource for Hematologic Disorders (U24)
    Donald Brambilla; Fiscal Year: 2013
    ..We also include personnel with experience in all aspects for clinical trials design, development, implementation and operations. (End of Abstract) ..
  52. TRAINING PROGRAM IN DEVELOPMENTAL HEMATOLOGY
    Alan L Schwartz; Fiscal Year: 2013
    ..program is the training of physician scientists in basic and applied research relevant to the causes of hematologic diseases in children...
  53. ERYTHROPOIESIS AND HEMOGLOBIN REGULATION IN MAN
    BLANCHE ALTER; Fiscal Year: 1990
    ..newborn infants, and fetuses, and from normals as well as patients with hemoglobinopathies, and other hematologic diseases. The progenitor cells will be cultured in semi-solid medium with added erythropoietin...
  54. Institutional Short-Term Research Training for Students of Diversity
    Bruce F Horazdovsky; Fiscal Year: 2012
    ..experiences under the guidance of a skilled mentor working in an area of cardiovascular, respiratory, or hematologic diseases research...
  55. Fetal Stem Cell Gene Therapy
    MARCUS MUENCH; Fiscal Year: 2003
    ..A positive outcome from the proposed studies would aid in developing treatments for hemoglobinopathies based on generating hematopoietic allochimerism. ..
  56. CONTROL OF COAGULATION
    WHYTE OWEN; Fiscal Year: 1990
    ..and biological role of these microparticles will be studied as well as their occurrence in a number of hematologic diseases. The coagulation system is implicated in the development of infective endocarditis, although initial ..
  57. Cell Graft Engineering Using Microfluids
    Allison Hubel; Fiscal Year: 2007
    ..cells grafts (both stem cells and mature cells) have become the standard of care for a wide range of hematologic diseases. Traditional methods of stem cell cryopreservation use dimethylsulfoxide (DMSO) as a cryoprotective agent ..
  58. 2010 Clinical Research Training Institute Summer Workshop
    John C Byrd; Fiscal Year: 2010
    ..More specific details on the Institute specific to this grant are posted on the PHS 398 Research Plan under Specific Aims, Background &Significance, and Research Design &Methods. ..
  59. Bone Marrow Failure Scientific Symposium
    Jaroslaw Maciejewski; Fiscal Year: 2004
    Bone marrow failure syndromes are severe hematologic diseases which can cause death due to low blood counts...
  60. Specialized Centers for Cell-Based Therapy for NHLBI an*
    Shelly Carter; Fiscal Year: 2009
    ..This includes treatments using cellular-based therapies in oncology, hematologic diseases, cartilage repair, diabetes, and initial work in cardiac and vascular repair...
  61. Heme Action in Neuronogenesis and Oxygen Sensing
    Li Zhang; Fiscal Year: 2005
    ..These studies will define the role of heme in neuronogenesis and in oxygen sensing and should provide insights into the molecular mechanisms underlying the pathogenesis of heme deficiency-related diseases. ..
  62. TRAUMA-RELATED ERYTHROPOIETIC SUPPRESSION
    David Livingston; Fiscal Year: 2003
    ..Failure of the stroma to grow in culture been demonstrated to correlate with BM failure in hematologic diseases. Stromal monolayers will be cultured with BM progenitors to assess whether they can support erythropoiesis ..